GCM
BIO icon

Gladius Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Gladius Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-96
Closed -$32.1K – 95
2024
Q3 		$32.1K Buy
+96
New +$30.5K 0.02% 202
2024
Q1 		– Sell
-121
Closed -$39.1K – 328
2023
Q4 		$39.1K Buy
121
+48
+66% +$15K 0.02% 213
2023
Q3 		$26.2K Buy
73
+18
+33% +$6.95K 0.01% 324
2023
Q2 		$20.8K Buy
+55
New +$22.4K 0.01% 302
2022
Q4 		– Sell
-75
Closed -$32K – 366
2022
Q3 		$32K Buy
+75
New +$37.4K 0.01% 293
2022
Q2 		– Sell
-190
Closed -$108K – 362
2022
Q1 		$108K Buy
+190
New +$115K 0.04% 213

Other funds holding BIO

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $18.8B AUM 17.33% 1-Year Est. Return